VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. - Wikidata - awgldk - TriplyDB

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

http://www.wikidata.org/entity/Q39181190

about

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Immune checkpoint inhibitors: therapeutic advances in melanoma Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Recent advances in understanding antitumor immunity Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53 Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.Annexin A1 in primary tumors promotes melanoma dissemination.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.Immunotherapy for advanced melanoma: future directions.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.Programming the immune checkpoint to treat hematologic malignancies.Leprosy as a model to understand cancer immunosurveillance and T cell anergy.Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.New B7 Family Checkpoints in Human Cancers.Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses.Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.Immune system and melanoma biology: a balance between immunosurveillance and immune escape.The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.Next generation immune-checkpoints for cancer therapy.Not All Immune Checkpoints Are Created Equal The immunological synapse

P2860

Q26769884-13A6FC97-E13D-48C3-86E3-97EB016F7B91 Q26775591-FAA7BC49-CF2A-474C-8187-571518C4DDFD Q28066199-67F24765-EAAB-4AEF-B624-49B0F602359B Q28067217-FE65C95B-9025-4F59-B4CF-3C0BCF525149 Q28072532-4CA68CAB-9AD4-418D-9527-4AE0A8C5C22D Q33632116-F8C453F9-F55F-427D-9BE8-6C0A59103BD1 Q34487653-137DDBA8-217B-4C85-A196-85198F1528C9 Q36382143-AA3779A4-D318-4F6D-B2AC-96E2F91F99D2 Q38305975-890296FF-4DA2-47CA-83E9-B856BB08D327 Q38636569-955C6C4B-A774-4F46-9B2F-0007F28E7EAB Q38710357-70881E6F-94EE-48A5-9088-2F71E1A7CE08 Q38711163-4AFDD1FD-13C3-4226-91D0-739AE0370BFF Q38779877-566EEDF1-1400-418D-9BBC-78181D1D3000 Q38796338-4B4F528E-66AD-4FCD-BCC8-378DBBC3A9BB Q38806070-245613FA-33C3-4815-B9EC-F9A531C58B1C Q38815454-FF2155AD-9D9E-4CEE-A7BC-49FC6728A9A7 Q38996594-5534E026-F368-47D3-80BA-69942487C6A8 Q39078341-965B05CD-0675-4D14-9DC2-3E09397F1910 Q39416195-E58E691D-EC12-495C-A39C-53E9F8B016AC Q41382123-4D11A27F-6721-423F-86F0-798227021520 Q41863599-44380E2F-1583-4DC8-8D0B-60EC54400ECF Q46971015-A966B1D2-024C-450A-94AD-350F7B9F1889 Q47139628-D2D9CF08-DA95-4582-9C35-39103B647596 Q47332473-2DD8F851-3500-461C-99EB-D1409DB7E5C2 Q47936526-0D60F496-E0EB-4210-8C4B-1869684255EF Q48156081-A25D4F8F-3442-4C7A-BBDE-1F68264E2185 Q48256829-D9B1E8FB-C98F-4FCF-8750-D48C21A9F7D5 Q49166036-26B0584F-1C04-47E7-BD20-EC445ED5B54A Q49545290-595C789F-53F7-4FCA-83AE-B6DA825392C8 Q52653710-D2F96F9F-7917-4D4B-B5F0-F2F9D5CA57CE Q52721812-E65583FF-7D84-4836-B089-83254D743C57 Q52801913-24234007-29C7-4D1F-B421-521856A88815 Q54960920-8223BBD7-715D-4603-89B0-5B086A08BC77 Q55020853-BEADE6A5-7A54-4766-99DE-494896ABB7B1 Q55060215-111BD21A-7832-4ACF-94CF-A8295BFCC272 Q55383705-499DEAD1-B0EF-4F87-AFA6-345ABCE8CDA6 Q56889626-8FA1BCCB-203D-4166-ABB2-751BE6051A2C Q57961866-F42CD795-BC20-4BA1-87FB-BEF9E831121A

P2860

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

http://www.wikidata.org/entity/Q39181190

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

@en

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

@nl

type

label

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

@en

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

@nl

prefLabel

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

@en

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

@nl

P1433

Q39181190-FF23DFBC-F357-4957-A82F-9D72A39D65E5

P1476

Q39181190-86FAD8A4-170D-4B35-83D4-5A8FEA8DE555

P2093

Q39181190-07450B86-24AA-4910-B53D-1149A46A55A0

Q39181190-61E75727-EFCB-4D44-89BC-EAFC5D5F1319

Q39181190-A182AFEB-B69F-4265-97AB-87156EB9C9C8

Q39181190-DE43EAFA-B1B8-4749-9823-B3CFBFB1DA5F

Q39181190-FCC9245B-047D-4506-8CCC-990492655E56

P2860

Q39181190-06F4F8C1-3D65-49BE-B9E1-928B1FEB438C

Q39181190-0B44F488-9B78-4E92-B299-ABCB194C9F1F

Q39181190-0D75D4B3-BB1F-44CE-9109-C47DCE045DDA

Q39181190-0EA5A9B3-5859-4D4E-B2AA-BBFD8DE46AA7

Q39181190-13248DE6-CDCC-4325-A52F-1854DA6809C3

Q39181190-13D1F9EC-EB33-4289-8C7A-0F24D3DFFDDB

Q39181190-1A148D4D-0CBB-4064-84E1-2FAA11C98C16

Q39181190-222529C8-EE42-4163-A9DC-8DAFD8C74AC0

Q39181190-23F23EFB-8830-4A44-ADF6-68DFF77D6EFE

Q39181190-2ABA45FD-64DF-497C-B494-C2D12D6A6E62

P304

Q39181190-9AA3BC46-32BF-48D9-8CA5-8C340D462DD9

P31

Q39181190-FADB5340-3786-4B95-9223-BB8C5CB20C26

P356

Q39181190-A941D164-E183-43A8-8F08-63AC3582CA58

P433

Q39181190-C70893AE-EF03-40D0-874B-9CE3F4B43FE0

P478

Q39181190-EE03757A-28C2-44CC-A6FF-9BB0FCF30A58

P577

Q39181190-A65B9291-C944-46BD-A2E6-43D2BE9EE23D

P698

Q39181190-0CE27F18-E8AC-4850-9768-B4B4765CF5FB

P921

Q39181190-ECF9F182-BA05-4B05-BA49-65BF061FA281

P932

Q39181190-6BD54BC7-7A78-4098-A9E8-9FBC7378FF5A

P356

2326-6066.CIR-14-0072

P1433

Cancer immunology research

P1476

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

@en

P2093

J Louise Lines

http://www.w3.org/2001/XMLSchema#string

Li Wang

http://www.w3.org/2001/XMLSchema#string

Lorenzo F Sempere

http://www.w3.org/2001/XMLSchema#string

Randolph Noelle

http://www.w3.org/2001/XMLSchema#string

Thomas Broughton

http://www.w3.org/2001/XMLSchema#string

P2860

Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens

B7x: a widely expressed B7 family member that inhibits T cell activation

Harnessing the potential of radiation-induced immune modulation for cancer therapy

CTLA-4 blockade in tumor models: an overview of preclinical and translational research

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

P304

510-517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-14-0072

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24894088

http://www.w3.org/2001/XMLSchema#string

P921

P932

4085258

http://www.w3.org/2001/XMLSchema#string